147 related articles for article (PubMed ID: 12771296)
21. Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism.
Nakanishi S; Yano S; Nomura R; Tsukamoto T; Shimizu Y; Shin J; Fukagawa M
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii47-9. PubMed ID: 12771300
[TBL] [Abstract][Full Text] [Related]
22. Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach.
Fukagawa M; Kitaoka M; Kurokawa K
Nephrol Dial Transplant; 1996; 11 Suppl 3():125-9. PubMed ID: 8840327
[TBL] [Abstract][Full Text] [Related]
23. Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients.
Onoda N; Kashiwagi T; Nakamura T; Niitsu Y; Omata M; Kurihara S
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S11-5. PubMed ID: 16109135
[TBL] [Abstract][Full Text] [Related]
24. Intervention for recurrent secondary hyperparathyroidism from a residual parathyroid gland.
Yumita S
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii62-4. PubMed ID: 12771304
[TBL] [Abstract][Full Text] [Related]
25. Local ethanol injection for the treatment of deltoid parathyroid cell hyperplasia.
Figari M; Musso CG; Plantalech L; Lambertini R; Rivera H; Mollerach A
Int Urol Nephrol; 2014 Jan; 46(1):247-9. PubMed ID: 23359107
[TBL] [Abstract][Full Text] [Related]
26. Hyperparathyroidism caused by distant pulmonary lesions and parathyromatosis after ethanol injection/parathyroidectomy for secondary hyperparathyroidism.
Nakamura M; Tanaka K; Fujii T
Hemodial Int; 2017 Jul; 21(3):E45-E49. PubMed ID: 28078796
[TBL] [Abstract][Full Text] [Related]
27. Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid in chronic dialysis patients--the Japanese strategy. Japanese Working Group on PEIT of Parathyroid, Tokyo, Japan.
Fukagawa M; Kitaoka M; Tominaga Y; Akizawa T; Kurokawa K
Nephrol Dial Transplant; 1999 Nov; 14(11):2574-7. PubMed ID: 10534489
[No Abstract] [Full Text] [Related]
28. Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention.
Kakuta T; Fukagawa M; Kitaoka M; Koiwa F; Onoda N; Tominaga Y; Akizawa T; Kurokawa K;
NDT Plus; 2008 Aug; 1(Suppl 3):iii21-iii25. PubMed ID: 25983968
[TBL] [Abstract][Full Text] [Related]
29. [Chronic kidney disease (CKD) and bone. The clinical perspective of parathyroid interventional therapy for advanced secondary hyperparathyroidism in the era of cinacalcet HCl].
Tominaga Y
Clin Calcium; 2009 Apr; 19(4):545-50. PubMed ID: 19329834
[TBL] [Abstract][Full Text] [Related]
30. Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
Koiwa F; Hasegawa T; Kojima I; Ideura T
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii53-7. PubMed ID: 12771302
[TBL] [Abstract][Full Text] [Related]
31. Effects of percutaneous ethanol injection therapy on subsequent parathyroidectomy.
Chen HH; Hsu MT; Wu CJ; Chen YW; Yang TL
Am J Surg; 2008 Aug; 196(2):155-9. PubMed ID: 18513687
[TBL] [Abstract][Full Text] [Related]
32. [Changes in serum intact parathyroid hormone levels and ultrasonic findings after percutaneous ethanol injection therapy in a patient with primary hyperparathyroidism].
Soma R; Takayama Y; Mimo T
Nihon Naibunpi Gakkai Zasshi; 1995 Jan; 71(1):53-64. PubMed ID: 7895865
[TBL] [Abstract][Full Text] [Related]
33. Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism.
Stratigis S; Stylianou K; Mamalaki E; Perakis K; Vardaki E; Tzenakis N; Katsipi I; Papavasiliou S; Yarmenitis S; Kyriazis J; Daphnis E
Clin Endocrinol (Oxf); 2008 Oct; 69(4):542-8. PubMed ID: 18331604
[TBL] [Abstract][Full Text] [Related]
34. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease.
Fukagawa M; Nakanishi S; Kazama JJ
Kidney Int Suppl; 2006 Jul; (102):S3-7. PubMed ID: 16810308
[TBL] [Abstract][Full Text] [Related]
35. Percutaneous ethanol injection therapy in post-transplant patients with secondary hyperparathyroidism.
Douthat WG; Orozco SE; Maino P; Cardozo G; de Arteaga J; de la Fuente J; Chiurchiu CR; Massari PU
Transpl Int; 2007 Dec; 20(12):1031-5. PubMed ID: 17883371
[TBL] [Abstract][Full Text] [Related]
36. Indication and efficacy of PEIT in the management of secondary hyperparathyroidism.
Koiwa F; Hasegawa T; Tanaka R; Kakuta T
NDT Plus; 2008 Aug; 1(Suppl 3):iii14-iii17. PubMed ID: 25983965
[TBL] [Abstract][Full Text] [Related]
37. Magnetic resonance imaging (MRI) and technetium-99m-methoxyisonitrile (MIBI) scintigraphy to evaluate the abnormal parathyroid gland and PEIT efficacy for secondary hyperparathyroidism.
Wada A; Sugihara M; Sugimura K; Kuroda H
Radiat Med; 1999; 17(4):275-82. PubMed ID: 10510900
[TBL] [Abstract][Full Text] [Related]
38. Long-term prognosis of parathyroid function for chronic dialysis patients after minimally invasive radioguided parathyroidectomy (MIRP).
Kakuta T; Suzuki Y; Tadaki F; Tanaka R; Tanaka S; Sakai H; Kurokawa K; Saito A
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii71-5. PubMed ID: 12771306
[TBL] [Abstract][Full Text] [Related]
39. [New interventions controlling parathyroid hormone].
Tominaga Y
Clin Calcium; 2004 Jan; 14(1):51-5. PubMed ID: 15576954
[TBL] [Abstract][Full Text] [Related]
40. Renoprotection following treatment of secondary hyperparathyroidism with percutaneous ethanol injection in pre-dialysis patients.
Chen HH; Chen YC; Yeh JC
Nephron; 2002 Sep; 92(1):105-10. PubMed ID: 12187092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
